This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

VYNE Therapeutics 경영진

경영진 기준 점검 2/4

VYNE Therapeutics CEO는 Dave Domzalski, Mar2020 에 임명되었습니다 의 임기는 6.33 년입니다. 총 연간 보상은 $2.33M, 27.4% 급여 및 72.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $3.53K 가치에 해당하는 회사 주식의 0.021% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 6.3 년과 5.3 년입니다.

핵심 정보

Dave Domzalski

최고경영자

US$2.3m

총 보수

CEO 급여 비율	27.36%
CEO 재임 기간	6.3yrs
CEO 지분 보유율	0.02%
경영진 평균 재임 기간	6.3yrs
이사회 평균 재임 기간	5.3yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Jun 27

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics press release (NASDAQ:VYNE): Q2 Non-GAAP EPS of -$0.13 beats by $0.02. Revenue of $0.13M (-55.2% Y/Y) beats by $0.03M. As of June 30, 2022, VYNE had cash and cash equivalents of $42.8 million. Shares -4% PM.

분석 기사 • Jul 02

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

분석 기사 • Mar 19

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jan 13

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Sales of Vyne Therapeutic's minocycline products were just $4 million last quarter which may hamper the company’s ability to sell or license the franchise. Vyne has shifted its focus from marketing the approved minocycline products to 3 pre-clinical assets which require substantial cash and expose investors to a high degree of clinical risk. The largest institutional shareholder has sold most of their position. The cash position is sufficient only through Q2 of 2022 and significant dilution is likely.

분석 기사 • Dec 03

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

분석 기사 • Aug 13

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Market forces rained on the parade of VYNE Therapeutics Inc. ( NASDAQ:VYNE ) shareholders today, when the analysts...

CEO 보수 분석

Dave Domzalski의 보수는 VYNE Therapeutics의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	n/a	n/a	-US$22m
Dec 31 2025	US$2m	US$638k	-US$27m
Sep 30 2025	n/a	n/a	-US$34m
Jun 30 2025	n/a	n/a	-US$39m
Mar 31 2025	n/a	n/a	-US$42m
Dec 31 2024	US$2m	US$638k	-US$40m
Sep 30 2024	n/a	n/a	-US$34m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$29m
Dec 31 2023	US$3m	US$638k	-US$28m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$638k	-US$34m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$40m
Mar 31 2022	n/a	n/a	-US$42m
Dec 31 2021	US$5m	US$638k	-US$44m
Sep 30 2021	n/a	n/a	-US$59m
Jun 30 2021	n/a	n/a	-US$69m
Mar 31 2021	n/a	n/a	-US$226m
Dec 31 2020	US$3m	US$501k	-US$256m

보상 대 시장: Dave의 총 보수(USD2.33M)는 US 시장에서 비슷한 규모 기업의 평균(USD653.62K)보다 높습니다.

보상과 수익: Dave의 보상은 회사가 적자임에도 증가했습니다.

CEO

Dave Domzalski (59 yo)

6.3yrs

재임 기간

US$2,330,560

보수

Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...

리더십 팀

이름	직위	재임 기간	보수	지분
David Domzalski	CEO, President & Director	6.3yrs	US$2.33m	0.021% $ 3.5k
Iain Stuart	Chief Scientific Officer	6.3yrs	US$1.01m	0.0057% $ 976.2
Mutya Harsch	General Counsel	6.3yrs	US$1.00m	0.0057% $ 976.2
Tyler Zeronda	CFO & Treasurer	5.1yrs	데이터 없음	0.0045% $ 762.2
Darrell Rigel	Consultant	7.7yrs	US$115.20k	데이터 없음

6.3yrs

평균 재임 기간

53yo

평균 나이

경험이 풍부한 관리: VYNE의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6.3 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
David Domzalski	CEO, President & Director	6.3yrs	US$2.33m	0.021% $ 3.5k
Sharon Surrey-Barbari	Independent Non Employee Director	6.3yrs	US$74.46k	0.000060% $ 10.2
Patrick LePore	Lead Independent Director	5.8yrs	US$76.96k	0.0031% $ 524.6
Steven Basta	Director	10.8yrs	US$56.20k	0% $ 0
Elisabeth Sandoval-Little	Independent Director	7.3yrs	US$71.20k	0% $ 0
Roy Fleischmann	Member of Scientific Advisory Board	4.8yrs	데이터 없음	데이터 없음
Martin Okun	Member of Scientific Advisory Board	4.8yrs	데이터 없음	데이터 없음
David Sachar	Member of Scientific Advisory Board	4.8yrs	데이터 없음	데이터 없음
Olaf Stuve	Member of Scientific Advisory Board	4.8yrs	데이터 없음	데이터 없음
Johnathan Whetstine	Member of Scientific Advisory Board	4.8yrs	데이터 없음	데이터 없음

5.3yrs

평균 재임 기간

64yo

평균 나이

경험이 풍부한 이사회: VYNE의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.3 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/27 20:15
종가	2026/07/27 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

VYNE Therapeutics Inc.는 9명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Douglas Tsao	Barclays
Jason Matthew Gerberry	BofA Global Research
Louise Chen	Guggenheim Securities, LLC

This company is no longer active

VYNE Therapeutics 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2025

Insufficient new directors

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Lead Independent Director recently bought US$51k worth of stock

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

Recent updates

Yarrow Bioscience, Inc. completed the acquisition of VYNE Therapeutics Inc. (NasdaqCM:VYNE) from AI Biotechnology LLC, Nantahala Capital Management LLC, and other shareholders in a reverse merger transaction.

New minor risk - Share price stability

VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026

First quarter 2026 earnings released: US$0.084 loss per share (vs US$0.20 loss in 1Q 2025)

VYNE Therapeutics Inc. Receives an Additional 180 Calendar Days Extension to Regain Compliance with the Minimum Bid Price Requirement

Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. (NasdaqCM:VYNE) in a reverse merger transaction.

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Notice of Non-Compliance with Nasdaq Listing Requirements

Insufficient new directors

First quarter 2025 earnings released: US$0.20 loss per share (vs US$0.15 loss in 1Q 2024)

Consensus EPS estimates upgraded to US$0.59 loss

New major risk - Market cap size

Price target decreased by 11% to US$5.50

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Consensus EPS estimates fall by 19%

VYNE Therapeutics Inc. Provides Program Update on Oral BET inhibitor VYN202

We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Consensus revenue estimates increase by 250%

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

VYNE Therapeutics Provides Update on VYN202 Program

Consensus revenue estimates fall by 20%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Inc. Therapeutics Reports Positive Top-Line Phase 1A MAD Data for VYN202, Its Novel BD2-Selective Bet Inhibitor

Consensus EPS estimates fall by 13%

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind